CNN (8/13, LaMotte ) reports, “Eating an anti-inflammatory diet of whole grains, fruits and vegetables instead of an inflammatory diet focused on red and processed meats and ultraprocessed foods, such as sugary cereals, sodas, fries and ice cream, lowered the risk of dementia by 31%, a new study found.” Researchers found “that benefit held true even for people with existing diagnoses of cardiometabolic conditions such as type 2 diabetes, heart disease or stroke.” The findings were published in JAMA Network Open.

Related Links:

— “Eating these foods lowers dementia risk, even with type 2 diabetes and heart disease, study says,”Sandee LaMotte, CNN, August 13, 2024

Healio (8/13, Herpen) reports research found that “a podcast that offers guidance for living with dementia as well as a space for those with lived experience to share their stories has received favorable reviews.” The Alzheimer Society teamed up “with the Centre for Education in Research in Aging and Health at Lakehead University in Ontario to produce Dementia Dialogue, a podcast dedicated to furthering education and creating dialogue around the issues that arise from a dementia diagnosis for patients and caregivers.” The findings were presented at the Alzheimer’s Association International Conference.

Related Links:

— “Eating these foods lowers dementia risk, even with type 2 diabetes and heart disease, study says,”Sandee LaMotte, CNN, August 13, 2024

The Washington Post (8/9, Gilbert , Ovalle , Roubein ) reported that on Friday, the Food and Drug Administration “rejected for now the first attempt to win approval of MDMA to treat post-traumatic stress disorder – a major blow for advocates who for decades have pushed to integrate illegal psychedelic drugs into mainstream medical care.” The agency has “requested another large study, which could take several years to conduct, according to” Lykos Therapeutics. The company “said it plans to contest the FDA’s request, saying it believes the existing data is adequate to prove the drug’s efficacy.”

The New York Times (8/9, Jacobs ) reported that following the FDA’s decision, “supporters of psychedelic medicine were deeply disappointed, and some said they were stunned, having assumed the therapy’s promising data would overcome flaws in the company’s clinical trials, which had been designed in consultation with F.D.A. scientists.” The agency “declined to discuss the decision or release the letter it sent to Lykos outlining its reasoning, citing confidentiality rules.” However, an FDA spokesperson said in a statement that the agency “will continue to encourage research and drug development that will further innovation for psychedelic treatments and other therapies to address these medical needs.”

The AP (8/9, Perrone ) reported that while disappointing for some, “the FDA’s decision was expected after a panel of government advisors voted overwhelmingly against the drug’s use for post-traumatic stress disorder in June.” The agency “said Friday the MDMA application had ‘significant limitations’ that ‘prevent the agency from concluding that the drug is safe and effective for the proposed indication.’”

Also reporting was Reuters (8/10, Roy, Sunny).

Related Links:

— “The Washington Post (requires login and subscription)

The New York Times (8/12, Jacobs ) reports, “The journal Psychopharmacology has retracted three papers about MDMA-assisted therapy based on what the publication said was unethical conduct at one of the study sites where the research took place.” The conduct in question involved “a sexual relationship” between “an unlicensed Canadian therapist who took part in the trial” and “a participant after the conclusion of the trial’s dosing sessions.” Multiple authors “are affiliated with Lykos Therapeutics, the drug company whose application for MDMA-assisted therapy to treat post-traumatic stress disorder was rejected last week by the Food and Drug Administration.” While Lykos “said the research in the retracted papers was not part of its application to the F.D.A.,” on Sunday the company “said that it disagreed with Psychopharmacology’s decision and that it would file an official complaint with the Committee on Publication Ethics.”

Related Links:

— “The New York Times (requires login and subscription)

Healio (8/12, Mahoney) reports, “Suicide rates among U.S. preteens increased significantly from 2008 to 2022, with the greatest increases being among Hispanic preteens and girls, according to a study.” Investigators also observed “the rate of suicide remained highest among Black preteens from both 2001 to 2007 (4.94 per 1 million persons) and 2008 to 2022 (8.5 per 1 million persons).” The findings were published in JAMA Network Open.

Related Links:

— “Suicide rates rise among preteens, with highest increases seen among Hispanic youth, girls,”Moira Mahoney, Healio, August 12, 2024